FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)															
1. Name and Address of Reporting Person* Bleichroeder LP				2. Issuer Name and Ticker or Trading Symbol DUOS TECHNOLOGIES GROUP, INC. [DUOT]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Officer (give title below) Other (specify below)						
(Last) (First) (Middle) 1345 AVENUE OF THE AMERICAS, 47TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 02/13/2020													
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _Form filed by More than One Reporting Person							
NEW YORK, NY 10105 (City) (State) (Zip)				Toble I. Non Desirative Scandida. Asset						ired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3)		2. Transaction 2 Date (Month/Day/Year) a		2A. Deemed Execution Date, if		3. Transact Code (Instr. 8)				uired (A)	(A) 5. Amount of Securities Beneficially Owned Followi Reported Transaction(s)		ties Following	6. Ownership Form:	7. Nature of Indirect Beneficial		
						Cod	e	V	Amount	(A) or (D)	Price	(Instr. 3	(Instr. 3 and 4)		Direct (D) or Indirect (I) (Instr. 4)		
Common Stock		02/13/202	.0			P			166,600	A	\$ 6	496,95	496,958		I	See footnote (2)	
Common Stock		02/13/202	20			P			1,200		\$ 5.9787 <u>(1)</u>	498,15	498,158		I	See footnote (2)	
Common Stock		02/14/202	2020			P			100	A	\$ 5.975	498,258		I	See footnote (2)		
Reminder:	Report on a s	separate line	for each class	s of securi	ities benefic	cially o	wned o		Per cor	sons who	respo	orm are	not requ	ction of inf lired to res OMB cont	pond unle	ss	1474 (9-02)
			Ta							Disposed of is, converti			y Owned				
	` `		on 3A. Deemed Execution Date,		e, if 4. Trans Code	4. 5. Number of		ative ities ared seed 3,	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Ti Amo Undo Secu	unt of criying rities r. 3 and Derivative Security (Instr. 5)		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owners Form of Derivat Securit Direct of Or India	f Beneficia Ownershi y: (Instr. 4)	
					Cod	e V	(A)	(D)	Da Ex		Expiration Date	on Title	Amount or Number of Shares				

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Bleichroeder LP 1345 AVENUE OF THE AMERICAS 47TH FLOOR NEW YORK, NY 10105		X				

Signatures

Michael M. Kellen, Chairman and CO-CEO of Bleichroeder LP	02/14/2020
-Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The reported price in Column 4 is a weighted average price. These shares were bought in multiple transactions. Prices ranged from \$5.97 to \$5.98 per share, inclusive. The (1) Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
 - The shares of Common Stock reported herein are indirectly beneficially owned by Bleichroeder, LP ("Bleichroeder"), a Delaware limited partnership, an investment adviser registered under the Investment Advisers Act of 1940. Bleichroeder is the registered investment adviser to Biotechnology Master Fund, Ltd. as well as to 21 April Fund, LP
- (2) and 21 April Fund, Ltd. (collectively, the "Funds"). The shares of Common Stock reported herein are directly held by the Funds. Bleichroeder disclaims beneficial ownership of the shares of Common Stock held directly by the Funds except to the extent, if any, of its pecuniary interest therein, and this report shall not be deemed an admission that Bleichroeder is the beneficial owner of any such securities.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.